|
US3108117A
(en)
|
1959-02-12 |
1963-10-22 |
Mead Johnson & Co |
3-benzyl-1, 2-diloweralkyl-3-pyrrolidinols
|
|
US3778443A
(en)
|
1969-02-13 |
1973-12-11 |
Ciba Geigy Ag |
4-tetrahydro pyridyl,hydroxy alkyl pyrazoles
|
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
|
GB1422263A
(en)
|
1973-01-30 |
1976-01-21 |
Ferrosan As |
4-phenyl-piperidine compounds
|
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
|
DE2701705A1
(de)
|
1976-01-28 |
1977-08-04 |
Sandoz Ag |
Neue organische verbindungen, ihre verwendung und herstellung
|
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
|
CA1146866A
(en)
|
1979-07-05 |
1983-05-24 |
Yamanouchi Pharmaceutical Co. Ltd. |
Process for the production of sustained release pharmaceutical composition of solid medical material
|
|
DE3438830A1
(de)
|
1984-10-23 |
1986-04-30 |
Rentschler Arzneimittel |
Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
ATE159426T1
(de)
*
|
1991-04-16 |
1997-11-15 |
Nippon Shinyaku Co Ltd |
Verfahren zur herstellung einer festen dispersion
|
|
US5817667A
(en)
|
1991-04-17 |
1998-10-06 |
University Of Georgia Research Foudation |
Compounds and methods for the treatment of cancer
|
|
US5340591A
(en)
|
1992-01-24 |
1994-08-23 |
Fujisawa Pharmaceutical Co., Ltd. |
Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
|
|
JP3265680B2
(ja)
|
1992-03-12 |
2002-03-11 |
大正製薬株式会社 |
経口製剤用組成物
|
|
AU4444393A
(en)
|
1992-09-01 |
1994-03-10 |
Zeneca Limited |
Pyrrolidine derivatives
|
|
GB9310713D0
(en)
|
1993-05-24 |
1993-07-07 |
Zeneca Ltd |
Aryl substituted heterocycles
|
|
DE69633607T2
(de)
|
1995-01-12 |
2006-02-23 |
Glaxo Group Ltd., Greenford |
Piperidinderivate mit tachykinin-antagonistischer wirkung
|
|
EP0755923B1
(en)
|
1995-01-23 |
2005-05-04 |
Daiichi Suntory Pharma Co., Ltd. |
Ameliorant or remedy for symptoms caused by Ischemic diseases and Phenylpiperidine compounds useful therefor
|
|
DE19504832A1
(de)
|
1995-02-14 |
1996-08-22 |
Basf Ag |
Feste Wirkstoff-Zubereitungen
|
|
HUP9900926A3
(en)
|
1995-09-07 |
2002-12-28 |
Hoffmann La Roche |
New 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
|
|
CA2229617A1
(en)
|
1995-10-20 |
1997-05-01 |
Dr. Karl Thomae Gmbh |
5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
EP0867183B1
(en)
|
1996-07-22 |
2004-10-06 |
Daiichi Suntory Pharma Co., Ltd. |
Arylpiperidinol and arylpiperidine derivatives and drugs containing the same
|
|
DE69837903T2
(de)
*
|
1997-08-11 |
2008-02-14 |
Pfizer Products Inc., Groton |
Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
|
|
US6274735B1
(en)
|
1998-08-10 |
2001-08-14 |
Hoffmann-La Roche Inc. |
Process and intermediates for preparation of substituted piperidines
|
|
IT1303737B1
(it)
|
1998-11-11 |
2001-02-23 |
Smithkline Beecham Spa |
Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
|
|
US20030017528A1
(en)
|
1998-11-20 |
2003-01-23 |
Ruoping Chen |
Human orphan G protein-coupled receptors
|
|
NZ511087A
(en)
|
1998-11-20 |
2004-01-30 |
Arena Pharm Inc |
Human orphan G protein-coupled receptors
|
|
ATE400252T1
(de)
*
|
1999-02-10 |
2008-07-15 |
Pfizer Prod Inc |
Pharmazeutische feste dispersionen
|
|
US6221660B1
(en)
|
1999-02-22 |
2001-04-24 |
Synaptic Pharmaceutical Corporation |
DNA encoding SNORF25 receptor
|
|
GB9912416D0
(en)
|
1999-05-28 |
1999-07-28 |
Pfizer Ltd |
Compounds useful in therapy
|
|
GB9923177D0
(en)
|
1999-09-30 |
1999-12-01 |
Pfizer Ltd |
Novel polypeptide
|
|
IL152925A
(en)
|
1999-10-21 |
2010-04-15 |
Pfizer |
Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
|
|
YU51701A
(sh)
|
2000-07-28 |
2003-12-31 |
Pfizer Inc. |
Postupak za dobijanje jedinjenja pirazola/4,3-d/ pirimidin-7-ona i njihovih derivata
|
|
US6770645B2
(en)
|
2001-03-16 |
2004-08-03 |
Pfizer Inc. |
Pharmaceutically active compounds
|
|
US6784185B2
(en)
|
2001-03-16 |
2004-08-31 |
Pfizer Inc. |
Pharmaceutically active compounds
|
|
WO2002088101A2
(en)
|
2001-04-27 |
2002-11-07 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of bace
|
|
US20030003157A1
(en)
|
2001-06-06 |
2003-01-02 |
University Of Medicine & Dentistry Of New Jersey |
Collagen compositions and methods for making and using the same
|
|
WO2003014110A1
(en)
|
2001-08-08 |
2003-02-20 |
Takeda Chemical Industries, Ltd. |
Benzazepine derivative, process for producing the same, and use
|
|
JP2005523260A
(ja)
*
|
2002-02-01 |
2005-08-04 |
ファイザー・プロダクツ・インク |
圧力ノズルを用いた均質噴霧乾燥固体非晶質薬剤分散体の製造方法
|
|
JPWO2003091216A1
(ja)
|
2002-04-25 |
2005-09-02 |
住友製薬株式会社 |
新規ピペリジン誘導体
|
|
GB0224919D0
(en)
|
2002-10-25 |
2002-12-04 |
Pfizer Ltd |
Triazole compounds useful in therapy
|
|
GB0230162D0
(en)
|
2002-12-24 |
2003-02-05 |
Metris Therapeutics Ltd |
Compounds useful in inhibiting angiogenesis
|
|
MXPA05009247A
(es)
|
2003-03-05 |
2006-05-19 |
Macchine Utensili Speciali S P |
Metodo de maquinado de un disco de freno.
|
|
GB0308333D0
(en)
|
2003-04-10 |
2003-05-14 |
Glaxo Group Ltd |
Novel compounds
|
|
EP1633737A1
(en)
|
2003-06-13 |
2006-03-15 |
Schering Aktiengesellschaft |
Quinolyl amide derivatives as ccr-5 antagonists
|
|
KR20060056944A
(ko)
|
2003-07-14 |
2006-05-25 |
아레나 파마슈티칼스, 인크. |
대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
|
|
ES2386354T3
(es)
|
2003-07-29 |
2012-08-17 |
Xenon Pharmaceuticals Inc. |
Derivados de piridilo y su uso como agentes terapéuticos
|
|
FR2862647B1
(fr)
|
2003-11-25 |
2008-07-04 |
Aventis Pharma Sa |
Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
|
|
US7235641B2
(en)
|
2003-12-22 |
2007-06-26 |
Micromet Ag |
Bispecific antibodies
|
|
EP1711491A1
(en)
|
2003-12-24 |
2006-10-18 |
Prosidion Limited |
Heterocyclic derivatives as gpcr receptor agonists
|
|
TW200538433A
(en)
|
2004-02-24 |
2005-12-01 |
Irm Llc |
Immunosuppressant compounds and compositiions
|
|
AU2005251909A1
(en)
|
2004-06-08 |
2005-12-22 |
Nsab, Filial Af Neurosearch Sweden Ab, Sverige |
New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
|
|
ATE534646T1
(de)
|
2004-10-29 |
2011-12-15 |
Zeria Pharm Co Ltd |
Carbazolderivat, solvat davon und pharmazeutisch unbedenkliches salz davon
|
|
TW200633990A
(en)
|
2004-11-18 |
2006-10-01 |
Takeda Pharmaceuticals Co |
Amide compound
|
|
GB0428526D0
(en)
|
2004-12-30 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
JP5208516B2
(ja)
|
2004-12-30 |
2013-06-12 |
エグゼリクシス， インコーポレイテッド |
キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
|
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
|
US8277495B2
(en)
|
2005-01-13 |
2012-10-02 |
Candela Corporation |
Method and apparatus for treating a diseased nail
|
|
AU2006216941B2
(en)
|
2005-02-16 |
2009-12-03 |
Pharmacopeia, Llc |
Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
|
|
AU2006247520A1
(en)
|
2005-05-18 |
2006-11-23 |
Wyeth |
3-cyanoquinoline inhibitors of TPL2 kinase and methods of making and using the same
|
|
WO2006133216A2
(en)
|
2005-06-06 |
2006-12-14 |
Smithkline Beecham Corporation |
4-substituted arylamine derivatives and their use in pharmaceutical compositions
|
|
JP2008543828A
(ja)
|
2005-06-15 |
2008-12-04 |
ファイザー・リミテッド |
ドーパミン作動薬としての３−フェニルアゼチジン誘導体
|
|
WO2007023507A2
(en)
|
2005-06-20 |
2007-03-01 |
Wockhardt Limited |
Oxazolidinones bearing antimicrobial activity composition and methods of preparation
|
|
JP5114395B2
(ja)
|
2005-06-30 |
2013-01-09 |
プロシディオン・リミテッド |
Ｇｐｃｒアゴニスト
|
|
WO2007003961A2
(en)
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
Gpcr agonists
|
|
RS20080112A
(sr)
|
2005-09-16 |
2009-05-06 |
Arena Pharmaceuticals Inc., |
Modulatori metabolizma i lečenje poremećaja koji su vezi sa njima
|
|
JP2009509988A
(ja)
|
2005-09-29 |
2009-03-12 |
サノフィ−アベンティス |
フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
|
|
WO2007066189A2
(en)
*
|
2005-12-09 |
2007-06-14 |
Pfizer Products Inc. |
Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
|
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
|
WO2008008887A2
(en)
|
2006-07-13 |
2008-01-17 |
Smithkline Beecham Corporation |
Gpr119 agonists for treating metabolic disorders
|
|
US8343548B2
(en)
*
|
2006-08-08 |
2013-01-01 |
Shin-Etsu Chemical Co., Ltd. |
Solid dosage form comprising solid dispersion
|
|
CA2661371A1
(en)
|
2006-08-30 |
2008-03-06 |
Biovitrum Ab (Publ) |
Pyrimidine compounds for treating gpr119 related disorders
|
|
ATE476966T1
(de)
*
|
2006-10-17 |
2010-08-15 |
Bend Res Inc |
Feste dispersion mit schwer wasserlöslichem wirkstoff
|
|
KR20090097184A
(ko)
|
2006-12-06 |
2009-09-15 |
스미스클라인 비참 코포레이션 |
비시클릭 화합물 및 항당뇨병제로서의 용도
|
|
CL2007003841A1
(es)
*
|
2006-12-28 |
2008-03-14 |
Metabolex Inc |
Compuestos derivados de 4(5h-1 lambda-tiazol-2-il)piperidina; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar diabetes.
|
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
|
WO2008109702A1
(en)
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
EP2014656A3
(en)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
|
JP5489997B2
(ja)
|
2007-07-19 |
2014-05-14 |
シマベイ セラピューティクス， インコーポレーテッド |
糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
|
|
UY31232A1
(es)
|
2007-07-19 |
2009-03-02 |
|
Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
|
|
FR2918986B1
(fr)
|
2007-07-19 |
2009-09-04 |
Sanofi Aventis Sa |
Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
|
|
EP2178861B1
(en)
|
2007-07-19 |
2014-08-20 |
Merck Sharp & Dohme Corp. |
Heterocyclic amide compounds as protein kinase inhibitors
|
|
JP2010533672A
(ja)
|
2007-07-19 |
2010-10-28 |
エフ．ホフマン−ラ ロシュ アーゲー |
新規ヘテロシクリル化合物およびケモカインアンタゴニストとしてのそれらの使用
|
|
EP2019104B1
(en)
|
2007-07-19 |
2013-09-04 |
Sanofi |
Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
|
|
AU2008331456A1
(en)
|
2007-12-04 |
2009-06-11 |
Merck Frosst Canada Ltd |
Renin inhibitors
|
|
US20090270404A1
(en)
*
|
2008-03-31 |
2009-10-29 |
Metabolex, Inc. |
Oxymethylene aryl compounds and uses thereof
|
|
US20110294836A1
(en)
|
2008-06-20 |
2011-12-01 |
Metabolex, Inc. |
Aryl gpr119 agonists and uses thereof
|
|
JPWO2010013849A1
(ja)
|
2008-08-01 |
2012-01-12 |
日本ケミファ株式会社 |
Ｇｐｒ１１９作動薬
|
|
AU2009290911A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
US20110160222A1
(en)
|
2008-11-26 |
2011-06-30 |
Metabolex, Inc. |
Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
|
|
CN102596177B
(zh)
|
2009-07-01 |
2014-05-28 |
阿昂梅迪克斯公司 |
来源于有核哺乳动物细胞的微囊泡及其应用
|
|
CN102666553B
(zh)
|
2009-10-01 |
2015-05-06 |
赛马拜制药公司 |
取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐
|
|
US20110313160A1
(en)
|
2010-06-04 |
2011-12-22 |
Metabolex, Inc. |
Preparation of 5-ethyl-2--pyrimidine
|
|
JP5847813B2
(ja)
|
2010-06-23 |
2016-01-27 |
シマベイ セラピューティクス， インコーポレーテッド |
５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
|
|
US20120184572A1
(en)
|
2011-01-13 |
2012-07-19 |
Metabolex, Inc. |
Aryl gpr119 agonists and uses thereof
|